NCT03564288View on ClinicalTrials.gov

Study to Find a Safe and Effective Dose of SKI-G-801 in the Treatment of Patients With Acute Myeloid Leukemia (AML)

PHASE1CompletedINTERVENTIONAL
Enrollment

14

Participants

Timeline

Start Date

February 23, 2018

Primary Completion Date

September 2, 2021

Study Completion Date

September 2, 2021

Conditions
Acute Myeloid Leukemia
Interventions
DRUG

SKI-G-801

SKI-G-801 is administered as an IV infusion over 10 minutes

Trial Locations (2)

90033

USC Norris Comprehensive Cancer Center, Clinical Investigations Support Office (CISO), 1441 Eastlake Ave., Rm. 7327, Los Angeles

90603

Innovative Clinical Research Institute, Whittier

Sponsors

Lead Sponsor

Oscotec Inc.

Collaborators (1)

PPD Development, LP
All Listed Sponsors
collaborator

PPD Development, LP

INDUSTRY

lead

Oscotec Inc.

INDUSTRY

NCT03564288 - Study to Find a Safe and Effective Dose of SKI-G-801 in the Treatment of Patients With Acute Myeloid Leukemia (AML) | Biotech Hunter | Biotech Hunter